Summary
4.39 0.39(9.75%)07/01/2024
Vigil Neuroscience, Inc. Common Stock (VIGL)
Vigil Neuroscience, Inc. Common Stock (VIGL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 9.75 | 2.80 | -61.13 | -47.78 | -63.00 | -73.06 | 0.00 | 0.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.39 | |
| Open | 4.00 | |
| High | 4.42 | |
| Low | 3.81 | |
| Volume | 730,356 | |
| Change | 0.39 | |
| Change % | 9.75 | |
| Avg Volume (20 Days) | 178,936 | |
| Volume/Avg Volume (20 Days) Ratio | 4.08 | |
| 52 Week Range | 2.97 - 13.55 | |
| Price vs 52 Week High | -67.60% | |
| Price vs 52 Week Low | 47.81% | |
| Range | 0.00 | |
| Gap Up/Down | -0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 164 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
06/27 09:06 EST - zacks.com
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).
06/27 08:11 EST - investorplace.com
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Vigil Neuroscience (NASDAQ: VIGL ) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ: SNY ). This investment has Sanofi purchasing 537,634 shares of Series A non-voting preferred shares at a price of $7.44 each.
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Vigil Neuroscience (NASDAQ: VIGL ) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ: SNY ). This investment has Sanofi purchasing 537,634 shares of Series A non-voting preferred shares at a price of $7.44 each.
06/27 02:00 EST - globenewswire.com
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - - Company expects proceeds to extend cash runway into 2026 - WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock.
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - - Company expects proceeds to extend cash runway into 2026 - WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock.
06/26 01:00 EST - businesswire.com
Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases
LEUVEN, Belgium--(BUSINESS WIRE)-- #ALS--Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gemma Fri.
Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases
LEUVEN, Belgium--(BUSINESS WIRE)-- #ALS--Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gemma Fri.
06/11 06:30 EST - investorplace.com
3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
Penny stocks have a unique appeal– one that only strong-stomached, risky-taking investors find appetizing. This is for good reason– these stocks are insanely volatile.
3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
Penny stocks have a unique appeal– one that only strong-stomached, risky-taking investors find appetizing. This is for good reason– these stocks are insanely volatile.
06/11 06:00 EST - investorplace.com
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.
05/30 07:05 EST - globenewswire.com
Vigil Neuroscience to Present in Upcoming June Investor Conferences
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management's participation at two upcoming investor conferences.
Vigil Neuroscience to Present in Upcoming June Investor Conferences
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management's participation at two upcoming investor conferences.
05/28 13:01 EST - zacks.com
All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
Vigil Neuroscience (VIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
Vigil Neuroscience (VIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
05/08 07:40 EST - globenewswire.com
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.
05/07 16:05 EST - globenewswire.com
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 –
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 –
04/17 16:05 EST - globenewswire.com
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology -
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology -
03/26 07:05 EST - globenewswire.com
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP –
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP –
03/20 07:05 EST - globenewswire.com
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer. Dr. Kaufmann succeeds Christopher J. Silber, M.D.
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer. Dr. Kaufmann succeeds Christopher J. Silber, M.D.
03/13 07:05 EST - globenewswire.com
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.
03/12 07:05 EST - globenewswire.com
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Tuesday, March 19th at 3:30 p.m. E.T.
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President will participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Tuesday, March 19th at 3:30 p.m. E.T.
03/06 16:25 EST - globenewswire.com
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to favorably tune microglia activation Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to favorably tune microglia activation
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to favorably tune microglia activation Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to favorably tune microglia activation
02/29 16:05 EST - globenewswire.com
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients' barriers to genetic testing
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients' barriers to genetic testing
02/07 16:05 EST - globenewswire.com
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, at 1:30 p.m. E.T.
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, at 1:30 p.m. E.T.
01/03 16:30 EST - globenewswire.com
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 -
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 -
11/22 16:05 EST - globenewswire.com
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, at 3:50 p.m. E.T.
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, at 3:50 p.m. E.T.